It may not be as easy for private biopharmaceutical companies to raise a new venture capital round in 2023 as it was during the past few years, but VC firms have brought in an impressive amount out cash for new funds to fuel further investment in the industry, including more than $1bn in new funds announced during the first week of April.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
